Denileukin diftitox
| Clinical data | |
|---|---|
| Trade names | Ontak, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611024 |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 70-80 min |
| Identifiers | |
| |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2560H4042N678O799S17 |
| Molar mass | 57647.46 g·mol−1 |
  (what is this?) (verify) | |
Denileukin diftitox, sold under the brand name Ontak among others, is an anti-cancer medication used for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.[3]
Medical uses
[edit]Denileukin diftitox is indicated for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.[1][2]
Adverse effects
[edit]The prescription label contains a boxed warning that capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.[1][2]
Society and culture
[edit]Legal status
[edit]In 1999, denileukin diftitox was approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma.[1][4]
References
[edit]- ^ a b c d "Ontak (denileukin diftitox) Injection for intravenous infusion Initial U.S. Approval: 1999". DailyMed. Retrieved 9 August 2024.
- ^ a b c https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761312s000lbl.pdf
- ^ Turturro F (January 2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Review of Anticancer Therapy. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516. S2CID 9028829.
- ^ Manoukian G, Hagemeister F (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy. 9 (11): 1445–51. doi:10.1517/14712590903348135. PMID 19817678. S2CID 23956460.
External links
[edit]- "Denileukin Diftitox (Code C1476)". NCI Thesaurus.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |